Oncolytic viruses are attractive therapeutics for cancer because they selectively amplify, through replication and spread, the input dose of virus in the target tumor. To date, clinical trials have demonstrated marked safety but have not realized their theoretical efficacy potential. In this review, we consider the potential of armed therapeutic viruses, whose lytic potential is enhanced by genetically engineered therapeutic transgene expression from the virus, as potential vehicles to increase the potency of these agents. Several classes of therapeutic genes are outlined, and potential synergies and hurdles to their delivery from replicating viruses are discussed.
T umor-selective, replication -competent oncolytic viruses offer several unique features as cancer therapeutics. First, the input dose is amplified in a tumor-dependent fashion. Consequently, even if only a small proportion of the input dose infects some of the target tumor cells, this infective dose should be capable of replicating in and eliminating neoplastic cells, using successive waves of replication and lysis until the tumor mass is completely destroyed. Importantly, these tumor-selective replication competent viruses spare normal tissue. Because replicationselective oncolytic viruses do not replicate efficiently in normal cells, the associated toxicities should be low. This property will become critical for systemic viral delivery to treat metastatic disease. Low toxicity creates an opportunity for the investigator to increase the dose of the therapeutic virus to overcome losses associated with nonspecific uptake or neutralization due to specific (e.g., antibodies ) and nonspecific (e.g., albumin ) factors. With their capacity to be carried passively throughout the body via the blood or lymph circulatory systems, these agents should be able to reach, infect, and similarly eliminate all metastatic lesions. These replication-competent, tumor-specific oncolytic viruses offer hope in the daunting field of cancer therapy.
A number of replication-competent, tumor-selective oncolytic viruses have entered the clinic. Clinical experiences show that these agents are safe, but are not potent enough as monotherapies to effect complete tumor regressions or to generate sustained clinical responses. Insufficient or inefficient infection of tumor cells is generally observed.
Three strategies are being pursued to overcome this weakness. One is to create less attenuated ( more potent ) viruses either through use of alternative viruses or by employing alternative, less attenuating, mechanisms for restricting replication to tumor cells. 1 -3 The second is to employ additional cytotoxic mechanisms, beyond the direct lytic functions of the virus, by arming these viruses with therapeutic genes. 4 Particularly attractive in this context are those cytotoxic mechanisms with potent bystander effects capable of eliminating tumor cells that the virus cannot reach. And the third is to combine the oncolytic viral therapy with the more traditional radiotherapy and /or chemotherapy, with which virotherapies often synergize. 5 This review will summarize current clinical results with replication -selective oncolytic viruses (Table 1 ). We will examine gene therapy strategies using nonreplicating viral vectors, as these inform current strategies for improving oncolytic therapies. Particular focus will be given to strategies for arming oncolytic viruses with therapeutic genes capable of eliciting antitumor immune function, inhibition of tumor neovascularization, or prodrug activation. Through synergistic combination of several cytotoxic modalities ( viral lysis, immune or antiangiogenic function, surgery and /or chemo -and radiotherapy ), therapies capable of eradicating tumors may be generated.
Oncolytic viruses
Since the early 1900s, reports of tumor regression correlating with either viral vaccination or infection have peaked interest in the oncolytic potential of viruses. The first clinical trial of replicating viruses (using wild -type adenoviruses ) was done in 1956. 6 There are suggestions of efficacy in the results of that trial, but lack of understanding of both the disease and 7 -14 In the clinical setting, these viruses have been administered by many routes: intratumoral, intravenous, intracranial, and intraperitoneal. Safety has been consistently high, toxicity very low, and only in the case of PV701 has a maximum tolerated dose (MTD ) been established. 12 Hundreds of courses of virotherapy have been given with no adverse events attributable to the virotherapy itself. For instance, one patient has received over 30 courses of PV701. 12 Especially encouraging is the observation that where preexisting and acquired neutralizing antibodies to these oncolytic agents have been demonstrated, there has been no correlation between these titers and efficacy. 5, 12, 15 To date, however, the clinical experience of these singleagent therapies has fallen short of their theoretical promise. In a few cases, full and relatively durable (up to 31 months ) cures have been achieved. 12 However, most patients have not experienced measurable regressions. With ONYX -015, the replication -selective oncolytic virus that has been most extensively tested and optimized in the clinic, only 14% of patients showed objective responses due to treatment. 9 Additionally, maintenance of regressions required continuous dosing. Once virotherapy was discontinued, patients suffered early relapses. However, the patients in these trials ( mostly Phase I) had failed multiple previous treatments, including surgery, chemo -, and radiotherapies and, consequently, it is commendable and encouraging in these early trials that even 14% of this group responded. However, the distance between the promise of complete and durable tumor eradication by the oncolytic virus, and the results outlined point to a need for improved virotherapy if this is to become a viable treatment for cancer patients in the clinic. In this review, we will examine strategies to increase the efficacy of oncolytic virotherapy through the addition of therapeutic transgenes to generate what have been termed ''armed therapeutic viruses'', 4 focusing on therapeutic genes currently being used in nonreplicating and replicating viral -based cancer gene therapies and the methods to control their expression in the context of the replicating virus. The potential synergies and challenges these therapeutic agents may hold for a replication -dependent viral -based therapy will also be discussed.
Armed therapeutic viruses
The experience of the oncologist in the clinic and our clearer understanding of the complexity and plasticity of human solid tumors dictate that combination therapies will need to be employed to generate effective, durable responses for the cancer patient. Armed therapeutic viruses that couple the lytic capability of the virus with the capacity to deliver therapeutic factors ( armed therapeutic viruses 4 ) to more effectively attack the complexity associated with human tumors, 16 then, is a natural evolution of the oncolytic virusbased therapy. This approach takes advantage of the viruses' ability to selectively replicate and spread in the tumor mass to safely and efficiently deliver therapeutic genes to target tissues where the therapeutic gene products can accumulate at times and to levels that afford maximal patient benefit. Choosing the appropriate gene( s ) with which to arm the oncolytic virus to enable it to arrest or eradicate the highly plastic, rapidly evolving tumor is a major question that has no simple answers. As a starting point it will be important to consider the potential interactions of the therapeutic factors with the viral -based therapies as a starting point. Several classes of gene therapy-based therapeutics have been traditionally associated with nonreplicating viral -based gene delivery vehicles ( antioncogenes, tumor suppressor genes, prodrug -converting enzymes, antiangiogenic, and immunology -based gene therapies ). We will briefly review these ''genetic payloads,'' examining the different factors as candidates for delivery from the oncolytic virus and potential issues surrounding each.
Tumor suppressors and antioncogenes as therapeutic transgenes
The study of cancer molecular biology has led to the discovery of a large variety of oncogenes and tumor suppressors whose aberrant expression or function causes oncogenic transformation. Numerous preclinical studies using replication -defective viruses have shown that restoration of tumor suppressor function, or inhibition of oncogene function, slows tumor growth and /or leads to apoptosis or cancer cell death. The theoretical bases for these virotherapies have been reviewed recently in several articles. One disadvantage of virotherapy strategies based on oncogene inhibition stems from the fact that only infected cells in which the transgene is expressed are killed. No bystander effects due to oncogene inhibition have been observed, i.e., uninfected tumor cells are not killed. Current virotherapy vectors are not efficient enough to insure infection of even the majority -much less all -of the tumor cells, even after intratumoral injection. A second disadvantage of using oncogene inhibitors or tumor suppressors to arm replication -competent oncolytic viruses is that the action of the inhibitors and suppressors, while toxic to the target tumor cell, is also likely to attenuate viral replication. 20 It may be that restraining expression of the oncogene inhibitor or tumor suppressor therapeutic transgene until late in the viral life cycle, when viral replication is essentially complete, would avoid this counterproductive conflict. 4 A third possible interference between this class of therapeutic transgenes and the replicating vector encoding them stems from the fact that tumor suppressors and oncogene inhibitors generally affect a number of pathways in the cell, any of which may compromise the engineered or endogenous tumor selectivity mechanism of the oncolytic virus or the viruses' ability to replicate in the target tumor cell. The former would be detrimental to safety, and the latter to efficacy.
However, therapies based on expression of tumor suppressors may be more effective than has been predicted based on their known mechanisms of action. For example, p53 gene transfer studies have unexpectedly demonstrated that the expression of p53 can trigger a number of events to generate beneficial bystander effects, 21 -23 any or all of which may synergize with the viral infection. More recently, investigators engineered the p53 gene into a replicating adenovirus from which it was expressed to high levels at late times postinfection. Surprisingly, this virus demonstrated enhanced preferential lysis of tumor cells to the exclusion of normal cells. 24 The ability of antioncogenes to synergize with the viral infection remains to be tested.
Prodrug therapies
The efficacy of traditional chemotherapies has been hampered by dose -limiting toxicities to normal cells. Prodrug therapies seek to reduce this toxicity by selectively generating the chemotherapeutic agent at the target tumor site. Such prodrug-based cancer therapies have two basic components: an inactive, nontoxic prodrug and a prodrugactivating enzyme (for a recent list, please see Ref. [ 15] ). In this anticancer strategy, the prodrug can (ideally ) be delivered systemically at high doses. The prodrug only becomes cytotoxic when activated by the appropriate enzyme. If the activating enzyme is expressed exclusively in tumor cells, then the prodrug will be activated, or become cytotoxic, only at the site of the target cancer cell. Ideally, once activated, the chemotherapeutic drug leaves the cell in an activated cytotoxic form to kill surrounding tumor cells ( local bystander effect ). Such bystander effects are particularly important to compensate for the inefficient infection and transduction of tumor cells by currently available vectors. Preclinical demonstrations of bystander effects using various prodrug and activating enzyme combinations have been published. In these studies, tumors composed of as few as 10% of prodrug -expressing cells were fully eradicated, whereas control tumors were not. 25, 26 However, the activated drugs' range would ideally be limited enough to restrict it from traveling into and damaging normal tissues. In other words, the active drug should have local bystander effect, but very limited or no distal bystander effect. 27 To try to ensure tumor cell -specific expression of the prodrug -activating enzymes, investigators have employed a number of methods including 1 ) intratumoral delivery, 2 ) tissue -or tumor-specific promoters (e.g., PSA, probasin ), and 3 ) engineering of the relevant transgenes into replication-competent, tumor-selective viral systems under the control of the HCMV promoter 28 or under the control of a native viral promoter. 29 Whereas prodrug-based therapies have been administered using a variety of vectors into various cancers, these therapies have not generated meaningful benefit in the clinical setting, presumably due to the poor distribution of the replication -defective viruses used as delivery vehicles. 30 If this is the limitation to these therapies, replication-competent oncolytic viruses encoding prodrug -activating enzymes may prove to be highly effective as they have been shown to increase levels and distribution of genomically encoded factors over replication -defective viruses. 31 Thymidine kinase ( TK ) and cytosine deaminase ( CD ) and their respective prodrugs [ganciclovir ( GCV ) and 5 -flourocytosine (5 -FC ), respectively ] are the most advanced of the prodrug -based therapies. Most recently, a gene fusion of CD /TK was engineered into a replication-competent, tumor-selective adenovirus and tested in a Phase I clinical trial on locally injectable prostatic tumors. The CD /TK fusion enzyme is a promising improvement for the oncolytic adenovirus because it saves genomic space, which is limited in adenovirus, without losing function. 32 In a 14-patient prostate cancer study, the virus was administered to the patients and, 2 days postinjection, the patients were given GCV and 5 -FC, with the GCV and 5-FC dosing continuing for a total of 7 days. Two of 14 patients experienced full tumor regression, and an additional four patients had partial regressions ( 25-80% reduction in PSA levels). No doselimiting toxicities were observed, and an MTD could not be reached. 28 These early trials indicate that this treatment, once optimized, may be both effective and safe.
Despite the encouraging initial data, prodrugs whose activated form interferes with DNA replication have been shown to limit the ability of the virus to continue to replicate and spread in the tumor. 33, 34 These reductions in viral burst size mitigate the cytolytic potential of these viruses and potentially compromise the full utility of this approach. To avoid interference between the therapeutic effects of direct viral lysis and drug -induced cytotoxicity, other prodrugs less toxic to the virus or more optimized dosing schedules will need to be developed. If this can be achieved, these virotherapies should be able to build upon the already encouraging clinical data being generated around combination therapies with the virus and chemotherapy. 5 As this approach should result in reduced systemic toxicities normally associated with chemotherapy, this treatment may also be combined with other treatment modalities such as radiotherapy or immunotherapy. Much current evidence indicates that combined modalities are considerably more successful in fighting cancer than any of the component monotherapies. 5,26,32,34 -40 
Antiangiogenic therapies
Unchecked cell proliferation is a hallmark of human cancers. The continued growth of the tumor, however, is dependent upon an adequate supply of oxygen and nutrients from the blood. 41, 42 When tumor growth exceeds the normal blood supply to a tissue or organ, new blood vessel formation must be stimulated from surrounding existing vessels to support continued tumor growth. This process, termed tumor neovascularization ( a special form of angiogenesis ), consists of multiple steps and includes local degradation of the capillary basement membrane, recruitment and proliferation of endothelial cells, and remodeling and formation of a network of new blood vessels.
Tumor neovascularization is an appealing target for cancer therapeutics for several reasons. First, because neovascularization or angiogenesis is a necessity for tumor growth, antiangiogenics could be applied to any solid tumor, regard-less of origin and independent of whether it is primary or metastatic disease. Second, because many of the angiogenesis inhibitors are ''natural'' (endogenous, nonsynthetic ), these may be well tolerated by the patient in contrast to traditional chemotherapeutics or small molecules, for example. 43, 44 Third, the target proliferating tumor endothelium differs significantly from the normal vascular endothelium in the adult. These differences range from proliferation rates ( the normal vascular endothelium is quiescent in the adult, with turnover times measured in hundreds of days 45 ) to gene expression profiles. 46 These differences offer potentially valuable targets for therapeutic intervention (see below ). Lastly, resistance to angiogenesis inhibitors is less likely to occur. Genetic instability is one of the trademarks of the cancerous cell and is the mechanism responsible for acquisition of drug resistance in cancer cells. In contrast to the cancer cell, the target of angiogenic therapy is a normal, genetically stable endothelial cell stimulated to proliferate and migrate in response to angiogenic stimulus from the tumor. With its genetic stability still intact, the normal endothelial cell is less likely to acquire a mutation conveying therapeutic resistance. Consequently, the development of angiogenesis inhibitors, or inhibitors of tumor neovascularization, has become a broad and active area of cancer research (for recent reviews, see Refs. [47] [48] [49] ).
More than 40 ''natural'' ( endogenous, nonsynthetic) inhibitors of angiogenesis have been discovered and characterized. 48 The development of these inhibitors as therapeutic agents, however, has been hampered by several factors including manufacturing difficulties, and stability and solubility issues. In addition, the majority of these agents are not directly cytotoxic to tumor cells and so it is likely that these angiogenesis inhibitors would need to be expressed on a continuous basis. Gene therapy offers one potential avenue to address many of these issues. The finding that susceptibility to angiogenesis inhibitors can vary by tumor stage 50 and the recent disappointments of antiangiogenic matrix metalloproteinase inhibitors in the clinic 51 have caused investigators to begin to turn their attention to systems where angiogenesis inhibitors can be combined with standard or experimental cancer therapies. 52, 53 In addition, more aggressive antiangiogenic therapies have begun to evolve in which investigators are developing systems to proactively eradicate the neovasculature 54, 55 in contrast to arresting its growth. Consequently, it is timely to consider inhibitors of angiogenesis in the context of armed therapeutic viruses (oncolytic viruses encoding therapeutic transgenes ). To date, however, replicating viruses encoding antiangiogenic therapeutic genes have not been reported.
Immunotherapy
The immune system is a complex mixture of effector molecules and cells that interact with one another to monitor and maintain the health of the host. Harnessing and targeting this potential into an effective therapy that selectively recognizes and eradicates the cancerous tissue remains a highly sought after, yet elusive, goal. Immunotherapy is based on the concept that there are differences between tumor cells and normal cells that can be detected by the immune system and can serve as targets for immune -mediated eradication of malignant disease. This is a very large and active field of gene therapy research and is at the center of the vast majority of the cancer gene therapy trials currently in the clinic. The use of cytokines, costimulatory molecules, and allogeneic major histocompatibility complex (MHC ) molecules; the delivery of tumor antigens to dendritic cells (DCs ); and the use of recombinant viruses expressing cancer antigens, alone or in combination with any of the previously described factors, all fall under this broad therapeutic umbrella directed at enhancing immune recognition, killing, and clearance of the target tumor cell.
These various strategies are commonly dependent on antigen -presenting cells (APCs) and cytotoxic T lymphocytes ( CTLs ). The APC is the sentinel for anomalies in the host. APCs include DCs, mononuclear -phagocytic cells, and activated B lymphocytes, with the DC serving as the target cell of choice for many cancer-based immunotherapies. This is because DCs are the most potent of the APCs, having a high capacity for antigen uptake in their immature form and high levels of MHC class I and II molecules, costimulatory molecules ( B7 -family ), and adhesion molecules (ICAM -1, LFA -3, CD11a,c ) in their mature form. These characteristics make them highly efficient at sampling the host environment, presenting antigen, and activating naïve T cells. 56 -61 In addition, methods for collecting and growing DCs from hematopoietic precursors have been described 58, 62, 63 and serve to increase their attractiveness as contributors in a therapeutic strategy.
A robust antitumor CTL response has traditionally been the goal of the immunotherapy approach to cancer treatment. The value of the CTL stems from several factors. First, it is specific. Short peptides, 8-11 amino acids in length, derived from proteasome-digested intracellular proteins are shuttled into the endoplasmic reticulum (ER ) by specialized transporters associated with antigen processing (TAP1 and TAP2 ) where they complex with MHC class I molecules. The MHC class I -peptide complex is consequently transported to the cell surface where it is recognized by the T-cell receptor (TCR ) of the CTL. In an oversimplification of a complex process, if the APC has appropriately directed the maturation of a CTL that specifically recognizes a tumor antigen, the CTL will act to destroy the cell by one of two pathways. In the first, the CTL, upon antigen recognition, releases perforin and granzyme B, the perforin acting to create pores in the target cell membrane, which the granzyme penetrates to trigger a caspase-mediated apoptotic cascade. 64, 65 An alternative pathway for CTL -mediated target cell killing involves a direct interaction between Fas ligand on the surface of the T lymphocyte and Fas receptor on the target cell, which also leads to caspase activation and apoptotic death of the target cell.
66,67 The cell killing event, then, is independent of other cell types and is, theoretically, longlived, reducing the chance for reoccurrence of the disease.
How tumors evade recognition and clearance by these potent immune mechanisms remains controversial. Detection of tumor antigen -reactive CD4 + and CD8 + T cells and antibodies directed against a wide variety of tumorassociated gene products in human patients who nonetheless
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Armed therapeutic viruses TW Hermiston and I Kuhn have measurable cancer adds to the evidence that, like many checkpoints to neoplastic disease, the immune response can be circumvented by the human tumor. 68 Consequently it is important to consider several points when immunostimulatory factors and the immune system are considered in association with the replicating viral agent. First, tumor cells evade, manipulate, and proactively attack immune components in order to survive and proliferate. Evasion of the APC can take several forms. These range from tumor-associated factors that inhibit the differentiation, maturation, and /or function of DCs, e.g., VEGF, IL -6, M -CSF, IL -10, PGE 2 , and TGF -b. 69, 79 Decreased recognition (e.g., loss of MHC class I molecules, loss of peptide transporters, alterations in proteasome function ), function ( e.g., decreased levels of TCR signaling pathway proteins CD3z, p56 lck , p59 fyn , and impaired NF -kB activation ), lack of appropriate stimuli ( tolerance, clonal deletion ), or T-cell survival (e.g., Fas ligand, MUC -1, B7 -H1 ) have all been described as tumorbased mechanisms to evade CTL -mediated eradication. 71 -85 These immune -evasive strategies are daunting, but viral infection may be a key to breaking immune tolerance of tumors. It has been proposed that cancer cells are not detected, or quickly become immunologically tolerated, because they are generally not presented to the immune system in a microenvironment that favors the activation of immune cells. An oncolytic virus, then, is an interesting system to consider as a vehicle to generate a systemic immune response to the target tumor. This is, in part, because it is clear that viruses are highly immunogenic, as measured by high levels of antibody and T cells responses described in the normal population for many of the viruses being considered for development of oncolytic viruses. This suggests that the viral infection has the ability to supply ''danger'' signals, thought necessary to attract and initiate the DC -mediated process of antigen uptake and presentation that ultimately, in theory, leads to the generation of the tumor-specific CTL response. This is the basis for the use of poxvirus-based vaccines for cancer therapy 86 that are now in various stages of clinical trials. Several oncolytic viruses of Ad and HSV origin are being engineered to encode immunostimulatory cytokines in an attempt to enhance their potential at eliciting a systemic immune response that complements the lytic function of the virus. 87 -91 Oncolytic viruses may also break immune tolerance of tumors by reducing tumor burden ( through viral lysis ) to a point below which an anti -tumor immune response can be effective. Several studies have indicated that immune dysfunction can be correlated with total tumor burden. 32, 81 An additional study has shown that the functional nature of the patient's immune response improved after debulking surgery. 92 Taken together, these studies indicate that lowering tumor burden through virus -induced cell death while stimulating antitumor immune response will increase the probability that a therapeutic systemic immune response will be elicited. Generating such a systemic immune response would be important to destroy metastatic disease.
While theoretically very inviting and well supported by preclinical studies, the ability to harness the immune system to generate long -term therapeutic benefit to the patient has not been realized yet in the clinic. Objective responses have been minimal and clear clinical benefit remains questionable. It should be noted that unlike classical vaccine studies performed prophylactically on healthy subjects, gene therapy -based cancer vaccine trials are faced with the challenge of generating an effective immune response to the target human tumor that has, by the time of its detection and the initiation of treatment, evolved in a variety of strategies to evade immune detection and eradication. It should also be noted that Phase I trials are conducted to determine the toxicity of the agent and are generally performed in latestage patients who have failed chemotherapy, radiation therapy, and /or surgery. This may not be an ideal population for many of the therapies that require a robust immune response. It is hoped that the safety of these agents might justify offering this treatment to early -stage patients, who are expected to have a better chance of mounting a strong immunebased defense and thereby benefiting from these therapies.
Controlling therapeutic transgene expression from ''armed'' replicating oncolytic viruses
While it is important to consider the therapeutic factors and how they may synergize with the oncolytic virus to maximize therapeutic benefit, it is equally important to consider how these factors will be genetically engineered into their respective viral genomes and how their expression will be controlled. While packaging of therapeutic genes is generally not an issue for large viruses like HSV ( nearly 50% of HSV genes are nonessential for viral replication 93 ) and vaccinia (where it is estimated that the virus may be able to package approximately 50 kb of foreign DNA 86 ), for smaller viruses like Ad, this is a considerable hurdle. For these viruses, gene delivery must be genomically economical. That is, consideration must be given to delivering as many therapeutic genes as possible from a genome that will only stably accommodate, in the case of Ad, approximately 2 kb of additional DNA beyond the size of the normal genome. 94 One strategy has been to generate multiple genes from a single transcript through the use of internal ribosome entry sites ( IRESs ), 95, 96 which have been successfully employed in replicating viruses. 24, 33 A second strategy offered by the replicating virus is to use the endogenous viral gene expression control machinery (promoter /enhancer, polyadenylation, and splice signals ) to deliver transgenes and, where possible, to selectively replace an individual viral gene or genes with a therapeutic gene of choice. In this strategy, therapeutic transgene expression should follow the normal kinetics of the endogenous substituted gene. If the expression kinetics of the individual sites is diverse, this should enable investigators to tailor their therapeutic gene expression to levels and times they deem optimal to generate maximal therapeutic benefit. If these substitutions do not alter the remaining surrounding genes in a complex transcription unit and these genes are nonessential to the viral life cycle in the infected tumor cell, the investigator may be able to substitute the remaining genes with additional therapeutic genes. In this fashion, a combination of genes that target totally different aspects of tumor biology ( e.g., prodrugconverting enzyme, immunostimulatory ) could be incorpo-rated into a single virus, synergizing with the inherent lytic property of the virus to attack the complexity of the tumor. This type of system has recently been described in the replicating Ad, 29, 91, 97, 98 developed in the nonessential, immunoregulatory E3 region transcription unit.
Native viral promoters offer several advantages as the transgene expression system in the armed therapeutic virus. For example, many of the mechanisms to derive tumor specificity are genetically engineered to be the earliest events ( i.e., attachment, penetration, immediate early gene expression ) in the viral life cycle or are native to the virus. As the tumor-selective mechanism will dictate whether the viral life cycle is allowed to proceed, viral promoters whose expression follows that gating event will not be expressed in a normal, nontumor cell. Linking therapeutic gene expression to the selectivity of the virus should restrict therapeutic gene expression to the target tumor and should exclude it from occurring in nontarget tissue. This is a very important consideration for a systemically administered oncolytic virus targeted at metastatic disease, where a wide array of cells may be exposed to the agent. Thus, a strategy using endogenous late ( in the viral life cycle ) promoters offers a level of controlled expression in the oncolytic virus that would not be present if a constitutively active promoter ( e.g., HCMV ) were used.
Native viral promoters may also offer well-characterized gene expression kinetics 29, 91, 97 and native viral promoters are optimized for expression in the virally infected cell. With the correct choice of gene insertion sites, it has been shown that a replication -competent virus using a native unmodified viral promoter can achieve levels of therapeutic gene expression superior to those seen with the very strong HCMV promoter /enhancer generated from a replicationincompetent agent. 91 Tissue -or tumor-specific promoters are also possibilities to convey tumor-specific therapeutic gene expression to the oncolytic virus. However, it is important to note that viral attachment and penetration events have the potential to make the nontarget normal cell appear to be a cancer cell to the tissue -or tumor-specific promoter. For example, the Ad penton protein (essential for penetration of the virus following attachment) interacts with a(v ) integrins, and triggers PI 3 kinase activity. 93 The PI 3 kinases are considered an excellent target for cancer-based therapies because they initiate complex signaling cascades that mediate proliferation, differentiation, chemotaxis, and survival. 94, 97, 98 As this pathway is associated with cancer, it may affect a promoter's ability to discern whether the infected cell is ''normal'' or ''tumor'' in origin. This does not exclude using tissue -or tumor-specific promoters but will require careful examination of each promoter in the context of each individual virus for its specificity.
Challenges for armed, replicating, oncolytic virus -based therapies
The mechanisms of each of the various classes of genebased therapeutics when used as monotherapies may be clear, but their potential interactions within the context of a replicating virus are not easily discerned. These interactions will either synergize to increase, or conflict to decrease, patient benefit. The actions of some therapeutic transgenes may synergize with one viral therapy, while interfering with another. Each combination therapy must be individually evaluated. For example, many of the gene -based therapeutic agents outlined previously in this review also have potential antiviral activities associated with them. In the case of the immunostimulatory factors, it is not only a consideration of the factor and its effect on the viral infection. There is also potential for redundant expression because the normal viral infection itself may stimulate various immunostimulatory factors (e.g., cytokines and chemokines ). In this context, even if there is redundancy, the investigator will need to give careful consideration to the levels and duration of this effect before simply dismissing some of these seemingly overlapping, or redundant, factors. As most of the prodrugconverting enzymes are targeted towards DNA integrity and replication, these factors and their incorporation into the viral genome would appear to be a significant challenge, requiring careful consideration of the dosing regimen or control of expression of these factors. In the case of antiangiogenic factors, consideration should be given to whether viral replication will be affected by growth in hypoxic cells. This is not to suggest that these challenges cannot be overcome. Instead, these examples are meant to facilitate thought and discussion on how to overcome these potential hurdles as these therapies make their way towards the clinic, and to point to the fact that each therapeutic will require considerable thought to maximize its potency in the tumor microenvironment in association with the replicating virus.
Conclusion
Human tumors are complex entities that continue to challenge modern medicine to develop more effective cancer therapies. Replication -competent oncolytic viruses, either naturally occurring or genetically engineered, represent a new class of agents being developed and tested in the clinical 3,8,10 -12,101,102 and preclinical settings. 103 -105 These agents, with their capacity to amplify their dose through replication at the target site, then spread within the tumor to lyse neoplastic cells and decrease the tumor burden, represent unique anticancer therapeutics. It is not clear from past studies or from our current understanding of various potential viral agents which virus ( or viruses) will best fulfill the oncolytic goals of sustained replication, exquisite specificity, and robust lytic activity when administered to the human tumor. Consequently, new oncolytic agents based on virus types already in the clinic ( e.g., Ad, HSV, Newcastle disease virus, reovirus ) or through alternative viruses ( e.g., measles, poliovirus, VSV, vaccinia ) must be explored. To effectively deal with the complex, heterogeneous nature of the tumor pool, however, the therapeutic transgene expression capacity of these viruses will likely also need to be developed. Armed therapeutic viruses, in which a therapeutic gene( s) is genetically engineered into the virus and dependent upon the continued selective replication of the virus for expression, represent a very appealing tumor treatment and a novel opportunity to generate a single agent that can attack tumors at multiple levels. In addition, it allows the investigator the flexibility to engineer additional factors into the virus to overcome potential or identified deficiencies of the therapy in the clinical setting. It is important to note that treatment with an armed therapeutic virus does not exclude the use of chemotherapy, radiation, or surgery. To the contrary, as reviewed here, theoretical considerations and clinical trial data strongly support the use of these agents in combination with the viral -based therapy. Consequently, armed therapeutic viruses represent a potentially exciting new treatment paradigm for human cancers.
